LEP and obesity disorder: A 12-month observational study of dapagliflozin in combination with dietary carbohydrate restriction and intervention by specialist weight-management dietitians throughout the study period showed decreases in body weight and blood leptin level but no changes in appetite in patients with obesity and type 2 diabetes [31].